Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína1. fázis

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
Guangdong Hengrui Pharmaceutical Co., Ltd
Hol
Wuhan (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
10 fő, tervezett
Kezdés
2025. nov. 12.
Várható befejezés
2026. nov.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • SHR-2173 Injection
A regiszteradat frissítve
2026. május 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP), a condition with low blood platelets. It tests multiple injections under the skin of SHR-2173.

Életkor
18 years or older
Nem
All sexes can join
A betegség stádiuma
Primary ITP diagnosed at least 3 months before screening. Platelet count below 30×10⁹/L, with a need for treatment. Stable condition with WHO bleeding grade 0-1.
Korábbi kezelés
Must have had corticosteroids before. The last ITP treatment stopped working, did not work, the disease came back, or it was not tolerated. Cannot have had SHR-2173 or spleen removal before.
Biomarker vagy leletérték
Platelet count below 30×10⁹/L. Normal prothrombin time and activated partial thromboplastin time (blood clotting tests).

A részvétel fő kizáró okai

  • ITP caused by another disease, or autoimmune hemolytic anemia
  • Blood clots within 12 months, clotting disorders, or blood thinners (except low-dose acetylsalicylic acid)
  • Life-threatening bleeding now, or active infection needing treatment
  • Myelodysplastic syndrome or cancer within 5 years, with some exceptions
  • Earlier stem cell or organ transplant, spleen removal, pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must fully understand the trial content, procedures, and potential adverse reactions, and voluntarily sign a written informed consent form (ICF)
  • Age at signing the ICF must be ≥ 18 years (including the boundary value), regardless of gender
  • Confirmed diagnosis of primary ITP for at least 3 months at screening
  • Previous treatment with corticosteroids
  • At the last ITP treatment, participants experienced loss of remission, no remission, relapse after remission, or intolerance
  • Platelet count <30×10⁹/L at screening with clinical assessment indicating treatment necessity
  • Participants must have adequate organ function
  • Clinically stable condition with World Health Organization (WHO) bleeding scale grade 0-1
  • Female participants of childbearing potential or male participants with fertile partners must refrain from sperm/ova donation from ICF signing until 12 weeks after last dose and agree to protocol-specified contraceptive measures

Ki nem vehet részt

  • Diagnosis of secondary thrombocytopenia or concomitant autoimmune hemolytic anemia
  • Received immunosuppressants (other than corticosteroids) such as Janus kinase [JAK] inhibitors or Bruton tyrosine kinase [BTK] inhibitors within either 5 times the drug elimination half-life or 14 days prior to the first infusion of SHR-2173 (whichever is longer)
  • Previous treatment with SHR-2173
  • Screening prothrombin time or activated partial thromboplastin time outside the normal range; concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medications (e.g., warfarin, clopidogrel, novel oral anticoagulants), except for low-dose acetylsalicylic acid
  • History of any thrombotic or embolic events within 12 months prior to the first administration, or clinical symptoms and history suggesting thrombophilia
  • Received live or attenuated live vaccines within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
  • Received live or attenuated live vaccines within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
  • Diagnosis of myelodysplastic syndrome; history of or current malignancy within 5 years prior to screening (except for cured non-melanoma skin cancer, in situ carcinoma [e.g., cervical, breast, bladder, prostate cancer], and cancers in complete remission for at least 5 years with no evidence of recurrence)
  • Previous splenectomy
  • Previous allogeneic stem cell or organ transplantation (except for corneal transplantation ≥ 3 months prior to screening); known or suspected history of immunosuppression
  • Planned surgery during the dosing period
  • Concurrent participation in other investigational studies within either 30 days prior to enrollment or 5 half-lives of the investigational drug (whichever is longer)
  • Current life-threatening bleeding (related to thrombocytopenia) or expected to require emergency treatment within one week after randomization
  • Active viral, bacterial, or other infections (including tuberculosis [TB]) requiring systemic treatment at screening, or SARS-CoV-2 infection during screening, or history of clinically significant recurrent infections
  • Any severe and/or unstable pre-existing medical, psychiatric, or other conditions that the investigator judges may interfere with patient safety, obtaining informed consent, or compliance with study procedures
  • Allergic constitution (e.g., allergies to two or more drugs, foods, or pollens) or known hypersensitivity (immediate or delayed) or atopic reactions to the study drug (including excipients, monoclonal antibodies)
  • Received platelet transfusion, whole blood transfusion, plasma exchange, or any other emergency treatment drugs within 14 days prior to the first infusion of SHR-2173
  • Females who are lactating or pregnant (positive serum or urine β-human chorionic gonadotropin [hCG]) at screening or on Day 1 of Week 1 prior to administration

Helyszínek itt: Kína

  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Heng Mei (principal investigator)Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients

A vizsgálat csoportja

  • SHR-2173 InjectionA vizsgált kezelés

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I Study Evaluating the Safety, Efficacy, Pharmacokinetics and Pharmacokinetics of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. május 28.